trimetazidine has been researched along with Cardiomyopathies, Primary in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Guieu, R; Maixent, JM; Paganelli, F; Pierre, SV; Sadrin, S | 1 |
| Chen, B; Dai, C; Li, J; Li, Y; Qi, Y; Wang, J | 1 |
| El-Khodary, NM; El-Tayaar, AA; El-Touny, EM; Ghoneim, AI | 1 |
| Chen, X; Dong, T; Du, L; Lin, Z; Xia, X; Zhou, H | 1 |
| Eid, BG; El-Shitany, NAE; Neamatallah, T | 1 |
| Fan, Q; Ma, L; Niu, Z | 1 |
| Kavtaradze, N; Saganelidze, K | 1 |
| Amin, MR; Arzu, J; Banerjee, RS; Ear-E-Mahabub, SM; Hoque, MH; Joarder, AI; Kabir, FI; Singha, CK; Zaman, SM | 1 |
| Handzlik-Orlik, G; Krysiak, R; Okopień, B; Sarnecki, K; Stadnik, M | 1 |
| Beker, DL; Fillmore, N; Jaswal, JS; Keung, W; Lopaschuk, GD; Mori, J; Ussher, JR; Wagg, CS | 1 |
| Belardinelli, R; Cianci, G; Gigli, M; Lacalaprice, F; Mazzanti, M | 1 |
| Belardinelli, R; Faccenda, E; Lacalaprice, F; Volpe, L | 1 |
| Chen, J; Li, C; Xu, W; Zhou, X | 1 |
| Abdel-Hady, S; El-Kady, T; El-Sabban, K; Gabaly, M; Sabry, A | 1 |
| Chen, XJ; Feng, L; Meng, D; Yang, D; Zhang, JN | 1 |
| Barkhudarian, AL; Sisakian, AS; Torgomian, AL | 1 |
| Adachi, N; Hayashi, K; Himei, H; Kondo, A; Matsuki, T; Matsuoka, T | 1 |
| Pogátsa, G | 1 |
| D'hahan, N; Janmot, C; Morel, JE; Taouil, K | 1 |
| Belardinelli, R; Purcaro, A | 1 |
| Boucher, F; de Leiris, J | 1 |
| Barat, JL; Bonnet, J; Boussens, B; Bricaud, H; Brottier, L; Combe, C | 1 |
5 review(s) available for trimetazidine and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Meta-analysis of trimetazidine treatment for cardiomyopathy.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Echocardiography; Female; Heart Function Tests; Humans; Male; Middle Aged; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2018 |
[MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Elapid Venoms; Heart; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, C-Type; Neoplasms; Survival Analysis; Trastuzumab; Trimetazidine; Troponin I | 2018 |
[Clinical aspects of the use of trimetazidine in the prevention and treatment of myocardial diseases].
Topics: Acidosis; Blood Glucose; Cardiomyopathies; Cardiotonic Agents; Diabetes Complications; Fatty Acids; Humans; Myocardium; Oxidation-Reduction; Trimetazidine | 2013 |
[New concepts in the therapy of diabetic cardiopathies].
Topics: Adenosine Triphosphate; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Trimetazidine | 1997 |
Ischemic myocardial cell necrosis: calcium overload or oxygen free-radicals?
Topics: Calcium; Cardiomyopathies; Coronary Disease; Free Radicals; Humans; Myocardial Reperfusion; Necrosis; Oxygen; Time Factors; Trimetazidine | 1990 |
9 trial(s) available for trimetazidine and Cardiomyopathies, Primary
| Article | Year |
|---|---|
The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients.
Topics: Angina Pectoris; Cardiomyopathies; Fibrosis; Humans; Inflammation; Myocardial Ischemia; Trimetazidine; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2023 |
Comparison between Glyceryl Trinitrate and Trimetazidine in Ischaemic Cardiomyopathy Patients.
Topics: Bangladesh; Cardiomyopathies; Humans; Male; Myocardial Contraction; Myocardial Ischemia; Nitroglycerin; Pilot Projects; Prospective Studies; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2019 |
Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Topics: Cardiomyopathies; Coronary Circulation; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Systole; Trimetazidine; Vasodilator Agents; Ventricular Function, Left | 2008 |
Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
Topics: Aged; Biomarkers; Blood Pressure; Body Mass Index; Brachial Artery; Cardiomyopathies; Combined Modality Therapy; Echocardiography, Doppler, Pulsed; Electrocardiography; Exercise Test; Exercise Therapy; Female; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Ischemia; Oxygen Consumption; Stroke Volume; Time Factors; Treatment Outcome; Trimetazidine; Vasodilation; Vasodilator Agents; Ventricular Dysfunction, Left | 2008 |
Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
Topics: Aged; Cardiomyopathies; Coronary Circulation; Echocardiography; Exercise Test; Female; Heart Function Tests; Hemodynamics; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Trimetazidine; Vasodilator Agents | 2005 |
[The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
Topics: Aged; Cardiomyopathies; Exercise; Exercise Tolerance; Female; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Ischemia; Trimetazidine; Vasodilator Agents | 2006 |
[Cardiac impairment of elderly patients with diabetes mellitus as studied with non-invasive myocardial scintigraphy and signal-averaged electrocardiography].
Topics: 3-Iodobenzylguanidine; Aged; Cardiomyopathies; Diabetes Complications; Electrocardiography; Heart; Humans; Iodine Radioisotopes; Iodobenzenes; Middle Aged; Tomography, Emission-Computed, Single-Photon; Trimetazidine; Vasodilator Agents | 1996 |
Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy.
Topics: Analysis of Variance; Cardiomyopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Trimetazidine; Vasodilator Agents; Ventricular Dysfunction, Left | 2001 |
Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.
Topics: Angina Pectoris; Cardiomyopathies; Coronary Disease; Double-Blind Method; Drug Evaluation; Female; Hemodynamics; Humans; Male; Middle Aged; Piperazines; Trimetazidine | 1990 |
8 other study(ies) available for trimetazidine and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Effects of long-term anti-ischemic drug treatment on Na,K-ATPase isoforms in cardiomyopathic hamsters.
Topics: Animals; Blotting, Western; Cardiomyopathies; Cricetinae; Heart; Ischemia; Isoenzymes; Male; Mesocricetus; Myocardium; Sodium-Potassium-Exchanging ATPase; Time Factors; Trimetazidine; Vasodilator Agents; Ventricular Remodeling | 2021 |
Trimetazidine Alleviates Postresuscitation Myocardial Dysfunction and Improves 96-Hour Survival in a Ventricular Fibrillation Rat Model.
Topics: Animals; Biomarkers; Cardiomyopathies; Cardiopulmonary Resuscitation; Inflammation; Rats; Rats, Sprague-Dawley; Stroke Volume; Trimetazidine; Ventricular Fibrillation; Ventricular Function, Left | 2022 |
Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition.
Topics: Animals; Cardiomyopathies; Epithelial-Mesenchymal Transition; Fibrosis; Human Umbilical Vein Endothelial Cells; Humans; NF-kappa B; Rats; Rats, Sprague-Dawley; Stroke Volume; Transforming Growth Factor beta; Trimetazidine; Ventricular Function, Left | 2022 |
Trimetazidine improved adriamycin-induced cardiomyopathy by downregulating TNF-α, BAX, and VEGF immunoexpression via an antioxidant mechanism.
Topics: Animals; Antioxidants; bcl-2-Associated X Protein; Cardiomyopathies; Doxorubicin; Oxidative Stress; Rats; Rats, Wistar; Trimetazidine; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2021 |
Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
Topics: Acetyl-CoA C-Acyltransferase; Animals; Cardiomyopathies; Echocardiography; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Obesity; Oxidation-Reduction; Palmitates; Trimetazidine; Vasodilator Agents | 2014 |
Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation.
Topics: Animals; Apoptosis; Cardiomyopathies; Cardiotonic Agents; Cytokines; Drug Evaluation, Preclinical; Gene Expression Regulation; Inflammation; Inflammation Mediators; Male; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Wistar; Smoking; Trimetazidine; Vasodilator Agents; Ventricular Remodeling | 2012 |
Trimetazidine improved Ca2+ handling in isoprenaline-mediated myocardial injury of rats.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Signaling; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Drug Combinations; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype.
Topics: Animals; Calcium Channel Blockers; Calcium-Transporting ATPases; Cardiomyopathies; Cricetinae; Electrophoresis, Polyacrylamide Gel; Mesocricetus; Myosins; Phenotype; Trimetazidine; Vasodilator Agents; Verapamil | 1998 |